ASCO: Low-Dose Chemo Benefits Advanced Gastroesophageal Cancer
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity
Gout Linked to Increased Risk for Venous Thromboembolism
Venous thromboembolism risk similar for patients with gout regardless of urate-lowering therapy
ASCO: Pembrolizumab Noninferior to Chemo in Advanced Gastric Cancer
For patients with PD-L1 combined positive score of ≥10, pembrolizumab prolongs overall survival
FDA Takes Hard Look at CBD
CBD products have swamped the market due to change in federal law, not because of new medical evidence
ACP Issues Position on Response to Physician Impairment
Rehabilitated doctors should be reintegrated into practice as long as patient safety not compromised
May 2019 Briefing – Hematology & Oncology
Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for May 2019. This roundup includes...
Guidelines Updated for Radiotherapy After Prostatectomy
Updates include adjuvant radiotherapy for patients with adverse pathologic findings, hormonal therapies
Lupus Manifestations Appear to Differ by Race, Ethnicity
Increased risk for severe manifestations seen among blacks, Hispanics, and Asians/Pacific Islanders
Excess Cause-Specific Mortality Tied to Chronic Proton Pump Inhibitor Use
Excess mortality due to CVD, CKD, upper GI cancer for those with no indication for PPI use
2007 to 2017 Saw Decline in Number of U.S. Pathologists
At the same time, the cancer-related diagnostic workload rose 42 percent per pathologist
